Search research articles
Contact Us
Filters
Showing results (121-130 of 195) with videos related to
Page
of 20
Sort By:
Transplantation and Cellular Therapy
|
April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy
Aasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Rawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy
|
September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
Anthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Journal of Hematology & Oncology
|
April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
Blood Cancer Discovery
|
May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignancies
Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica
|
April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Jennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood Advances
|
January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology
|
March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 195) with videos related to
Sort By:
Page
of 20
Transplantation and Cellular Therapy
|
April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy
Aasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Rawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy
|
September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
Anthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Journal of Hematology & Oncology
|
April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
Blood Cancer Discovery
|
May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignancies
Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica
|
April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Jennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood Advances
|
January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology
|
March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Page
of 20